Payment overview · 2025
General Payments
$206.89
8 reported records · 5 companies
Healthcare provider profile · identity verified
Howard Avery Schneider, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · CHEYENNE, WY · NPI 1629188552
Verified facts
What the public records show
CMS Open Payments records show Howard Avery Schneider, MD received $206.89 in general payments during 2025 across 8 reported records.
UCB, Inc. accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Enbrel by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $77.54 | 37.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.13 | 32.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.63 | 12.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.01 | 8.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.58 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.89 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $77.54 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 908 | 242 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 759 | 162 |
| Methotrexate | Methotrexate Sodium | 510 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 303 | 33 |
| Leflunomide | Leflunomide | 271 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 228 | 60 |
| Nifedipine Er | Nifedipine | 189 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 31 |
| Losartan Potassium | Losartan Potassium | 143 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 41 |
| Omeprazole | Omeprazole | 134 | 25 |
| Folic Acid | Folic Acid | 125 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 28 |
| Warfarin Sodium | Warfarin Sodium | 115 | 15 |
| Lisinopril | Lisinopril | 109 | 24 |
| Gabapentin | Gabapentin | 105 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 11 |
| Alprazolam | Alprazolam | 95 | 23 |
| Furosemide | Furosemide | 94 | 27 |
| Potassium Chloride | Potassium Chloride | 92 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 91 | 23 |
| Tramadol Hcl | Tramadol Hcl | 84 | 13 |
| Spironolactone | Spironolactone | 79 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 19 |
| Eliquis | Apixaban | 61 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 43 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 60 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 11 |
| Humira(Cf) Pen | Adalimumab | 50 | suppressed |
| Simvastatin | Simvastatin | 50 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Azathioprine | Azathioprine | 44 | suppressed |
| Rinvoq | Upadacitinib | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Enbrel | Etanercept | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.89 · 8 records | UCB, Inc. | Bimzelx, KEVZARA, RINVOQ, TAVNEOS, VELSIPITY, XELJANZ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rinvoq play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error